Login / Signup

The dichotomy of glucocorticosteroid treatment in immune-inflammatory rheumatic diseases: an evidence-based perspective and insights from clinical practice.

Elvis HysaTamara VojinovicEmanuele GotelliElisa AlessandriCarmen PizzorniSabrina PaolinoAlberto SulliVanessa SmithMaurizio Cutolo
Published in: Reumatologia (2023)
Glucocorticosteroids' use in treating IRDs should be judicious, focused on minimizing use, tapering and discontinuing treatment, when possible, to improve long-term safety. Glucocorticosteroids remain part of many therapeutic regimens, particularly at low doses, and elderly RA patients, especially with associated chronic comorbidities, may benefit from long-term low-dose GC treatment. A personalized GC therapy is essential for optimal long-term outcomes.
Keyphrases